234 related articles for article (PubMed ID: 28933295)
1. Applications of Multi-Target Computer-Aided Methodologies in Molecular Design of CNS Drugs.
Raevsky OA; Mukhametov A; Grigorev VY; Ustyugov A; Tsay SC; Jih-Ru Hwu R; Yarla NS; Tarasov VV; Aliev G; Bachurin SO
Curr Med Chem; 2018; 25(39):5293-5314. PubMed ID: 28933295
[TBL] [Abstract][Full Text] [Related]
2. CNS drug development - lost in translation?
Talevi A; Bellera CL; Di Ianni M; Gantner M; Bruno-Blanch LE; Castro EA
Mini Rev Med Chem; 2012 Sep; 12(10):959-70. PubMed ID: 22420574
[TBL] [Abstract][Full Text] [Related]
3. Changing Paradigm from one Target one Ligand Towards Multi-target Directed Ligand Design for Key Drug Targets of Alzheimer Disease: An Important Role of In Silico Methods in Multi-target Directed Ligands Design.
Kumar A; Tiwari A; Sharma A
Curr Neuropharmacol; 2018; 16(6):726-739. PubMed ID: 29542413
[TBL] [Abstract][Full Text] [Related]
4. Tools in the Design of Therapeutic Drugs for CNS Disorders: An up-to-date Review.
Sahu JK; Mishra AK
Curr Mol Pharmacol; 2018; 11(4):270-278. PubMed ID: 30129422
[TBL] [Abstract][Full Text] [Related]
5. In Silico Studies in Drug Research Against Neurodegenerative Diseases.
Makhouri FR; Ghasemi JB
Curr Neuropharmacol; 2018; 16(6):664-725. PubMed ID: 28831921
[TBL] [Abstract][Full Text] [Related]
6. CADD Modeling of Multi-Target Drugs Against Alzheimer's Disease.
Ambure P; Roy K
Curr Drug Targets; 2017; 18(5):522-533. PubMed ID: 26343117
[TBL] [Abstract][Full Text] [Related]
7. Discovery of multitarget-directed ligands against Alzheimer's disease through systematic prediction of chemical-protein interactions.
Fang J; Li Y; Liu R; Pang X; Li C; Yang R; He Y; Lian W; Liu AL; Du GH
J Chem Inf Model; 2015 Jan; 55(1):149-64. PubMed ID: 25531792
[TBL] [Abstract][Full Text] [Related]
8. Drug Design for CNS Diseases: Polypharmacological Profiling of Compounds Using Cheminformatic, 3D-QSAR and Virtual Screening Methodologies.
Nikolic K; Mavridis L; Djikic T; Vucicevic J; Agbaba D; Yelekci K; Mitchell JB
Front Neurosci; 2016; 10():265. PubMed ID: 27375423
[TBL] [Abstract][Full Text] [Related]
9. Current State and Future Perspectives in QSAR Models to Predict Blood- Brain Barrier Penetration in Central Nervous System Drug R&D.
Morales JF; Montoto SS; Fagiolino P; Ruiz ME
Mini Rev Med Chem; 2017; 17(3):247-257. PubMed ID: 27739359
[TBL] [Abstract][Full Text] [Related]
10. Multi-Target Directed Drugs as a Modern Approach for Drug Design Towards Alzheimer's Disease: An Update.
de Freitas Silva M; Dias KST; Gontijo VS; Ortiz CJC; Viegas C
Curr Med Chem; 2018; 25(29):3491-3525. PubMed ID: 29332563
[TBL] [Abstract][Full Text] [Related]
11. Molecular mapping in the CNS.
Wong MG; Tehan BG; Lloyd EJ
Curr Pharm Des; 2002; 8(17):1547-70. PubMed ID: 12052200
[TBL] [Abstract][Full Text] [Related]
12. Computer Aided Drug Design for Multi-Target Drug Design: SAR /QSAR, Molecular Docking and Pharmacophore Methods.
Abdolmaleki A; Ghasemi JB; Ghasemi F
Curr Drug Targets; 2017; 18(5):556-575. PubMed ID: 26721410
[TBL] [Abstract][Full Text] [Related]
13. Challenges in the search for drugs to treat central nervous system disorders.
Enna SJ; Williams M
J Pharmacol Exp Ther; 2009 May; 329(2):404-11. PubMed ID: 19182069
[TBL] [Abstract][Full Text] [Related]
14. The value of PET ligand discovery to CNS drug development.
Schmidt ME; Andrés JI
Future Med Chem; 2017 Mar; 9(4):351-356. PubMed ID: 28263084
[No Abstract] [Full Text] [Related]
15. Advances in quantitative structure-activity relationship models of anti-Alzheimer's agents.
Ambure P; Roy K
Expert Opin Drug Discov; 2014 Jun; 9(6):697-723. PubMed ID: 24754675
[TBL] [Abstract][Full Text] [Related]
16. Multitarget drug discovery projects in CNS diseases: quantitative systems pharmacology as a possible path forward.
Geerts H; Kennis L
Future Med Chem; 2014; 6(16):1757-69. PubMed ID: 25574530
[TBL] [Abstract][Full Text] [Related]
17. Tacrine-resveratrol fused hybrids as multi-target-directed ligands against Alzheimer's disease.
Jeřábek J; Uliassi E; Guidotti L; Korábečný J; Soukup O; Sepsova V; Hrabinova M; Kuča K; Bartolini M; Peña-Altamira LE; Petralla S; Monti B; Roberti M; Bolognesi ML
Eur J Med Chem; 2017 Feb; 127():250-262. PubMed ID: 28064079
[TBL] [Abstract][Full Text] [Related]
18. Start small and stay small. Minimizing attrition in the clinic with a focus on CNS therapeutics.
Nienaber V
Curr Top Med Chem; 2009; 9(18):1688-704. PubMed ID: 19929834
[TBL] [Abstract][Full Text] [Related]
19. Structural modifications that alter the P-glycoprotein efflux properties of compounds.
Hitchcock SA
J Med Chem; 2012 Jun; 55(11):4877-95. PubMed ID: 22506484
[No Abstract] [Full Text] [Related]
20. Modulation of the vasopressin system for the treatment of CNS diseases.
Ryckmans T
Curr Opin Drug Discov Devel; 2010 Sep; 13(5):538-47. PubMed ID: 20812145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
